{"entity":{"id":"epha6","kind":"target","name":"EPHA6","aka":["EPH receptor A6","Ephrin type-A receptor 6","FLJ35246"],"tldr":"EPHA6 (Ephrin type-A receptor 6) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","summary":"Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling.\n\nOpen Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.44, animal model 0.53, genetic association 0.33, clinical 0.93).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:19296","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19296"},{"label":"UniProt Q9UF33","url":"https://www.uniprot.org/uniprotkb/Q9UF33/entry"},{"label":"NCBI Gene 285220","url":"https://www.ncbi.nlm.nih.gov/gene/285220"},{"label":"Ensembl ENSG00000080224","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080224"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["thyroid","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.93. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"EPHA6","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:19296","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19296","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UF33","url":"https://www.uniprot.org/uniprotkb/Q9UF33/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000080224","url":"https://platform.opentargets.org/target/ENSG00000080224/associations","note":"association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: thyroid cancer 0.56, neuroendocrine neoplasm 0.54 (GraphQL API, CC0)"}],"hgnc":"HGNC:19296","ensembl":"ENSG00000080224","uniprot":"Q9UF33","entrez":"285220","biology":"Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Location: Membrane (UniProt). Locus 3q11.2 (HGNC).","whereFound":["Thyroid cancer: Open Targets association 0.56 with thyroid cancer (MONDO_0002108)","Neuroendocrine tumours: Open Targets association 0.54 with neuroendocrine neoplasm (MONDO_0019496)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/epha6/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}]}}